DUBLIN – Health care investor Syncona Ltd. has founded a new startup, Purespring Therapeutics Ltd., to take gene therapy into the kidney. It is committing £45 million (US$59.6 million) in series A funding, which will support the build-out of the new company and take at least one program into the clinic.

Biopharmas raising money in public or private financings, including: Achilles, Beyondspring, CASI, Imago, Immutep, Juventas, Meiragtx, Olema, Stoke, Therapix.

Med-tech firms raising money in public or private financings, including: Bausch Health Companies.

Biopharmas raising money in public or private financings, including: 4D Molecular, Beyondspring, Briacell, Elevation, Emergex, Evommune, Five Prime, Gan & Lee, Hemogenyx, Keros, Kodiak, Oblique, Oncternal, Oric, Pharvaris, Population Health Investment, Qiming, Scopus, Umoja, Xiaomi.

Med-tech firms raising money in public or private financings, including: Alivecor, Guardant Health, Hutchison China Meditech.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Adagio, Edoc Acquisition.

Biopharmas raising money in public or private financings, including: D3, Histogen, Hutchison, Inmed, Kodiak, Lixte, Promis, Sapience, Ysopia.

Adagio Medical Inc., a company focused on the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), has scooped up $42.5 million in a series E equity financing. The funds are earmarked for the ongoing IDE trial of its intelligent Continuous Lesion Ablation System (iCLAS). They will also be used to accelerate the European VT CE mark study, advance the commercialization of iCLAS in CE-mark countries and further development and clinical validation of its pulsed field cryoablation technology.

Med-tech firms raising money in public or private financings, including: Intervenn Biosciences.